[ACRX] AcelRx Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 2.85 Change: 0.05 (1.79%)
Ext. hours: Change: 0 (0%)

chart ACRX

Refresh chart

Strongest Trends Summary For ACRX

ACRX is in the long-term down -65% below S&P in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain (BTP). Its principal product candidate is Zalviso, an investigational pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. The company is also developing ARX-04, a Sufentanil Single-Dose NanoTab, which has completed Phase II clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as on the battlefield, in the emergency room, or in ambulatory care facilities. In addition, its product candidate pipeline consists of ARX-02, a Sufentanil NanoTab pain management system, which has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain (BTP);

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.04 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 154.93% Sales Growth - Q/Q-19.91% P/E-2.31
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-44.64% ROE-82.14% ROI-58.1%
Current Ratio4.26 Quick Ratio Long Term Debt/Equity0.32 Debt Ratio0.37
Gross Margin Operating Margin-763.87% Net Profit Margin-636.39% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities370 K Cash From Investing Activities-510 K Cash From Operating Activities-10.75 M Gross Profit
Net Profit-10.03 M Operating Profit-11.4 M Total Assets75.59 M Total Current Assets65.42 M
Total Current Liabilities15.36 M Total Debt25.14 M Total Liabilities34.51 M Total Revenue180 K
Technical Data
High 52 week5.5 Low 52 week1.7 Last close3.65 Last change-1.35%
RSI77.78 Average true range0.2 Beta0.78 Volume150.74 K
Simple moving average 20 days12.39% Simple moving average 50 days34.74% Simple moving average 200 days46.59%
Performance Data
Performance Week8.96% Performance Month46% Performance Quart71.76% Performance Half69.77%
Performance Year63.68% Performance Year-to-date80.25% Volatility daily3.96% Volatility weekly8.87%
Volatility monthly18.17% Volatility yearly62.94% Relative Volume149.89% Average Volume522.21 K
New High New Low


2020-06-04 08:13:59 | The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic

2020-06-03 18:50:00 | AcelRx Pharmaceuticals Announces It Will Not Further Revise Its Offer to Acquire Tetraphase

2020-06-01 20:00:00 | AcelRx Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

2020-05-29 08:30:00 | AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase

2020-05-27 11:54:35 | Hedge Funds Have Never Been Less Bullish On AcelRx Pharmaceuticals Inc ACRX

2020-05-27 09:54:00 | AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase

2020-05-12 15:20:30 | Edited Transcript of ACRX earnings conference call or presentation 11-May-20 8:30pm GMT

2020-05-12 03:00:49 | AcelRx Pharmaceuticals Inc ACRX Q1 2020 Earnings Call Transcript

2020-05-11 18:45:10 | AcelRx Pharmaceuticals ACRX Reports Q1 Loss, Misses Revenue Estimates

2020-05-11 16:01:00 | AcelRx Pharmaceuticals Reports First Quarter 2020 Financial Results

2020-05-10 15:40:37 | The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

2020-05-08 12:00:04 | All You Need to Know About AcelRx Pharmaceuticals ACRX Rating Upgrade to Buy

2020-05-08 09:09:01 | Is a Beat in Store for Sunoco SUN This Earnings Season?

2020-05-07 12:55:11 | Bidding War Sends Tetraphase Shares Soaring

2020-05-06 12:30:04 | AcelRx Pharmaceuticals ACRX Expected to Beat Earnings Estimates: Should You Buy?

2020-05-05 12:51:04 | Tetraphase TTPH to Post Q1 Earnings: What's in the Cards?

2020-05-04 16:35:00 | AcelRx to Host First Quarter 2020 Financial Results Call and Webcast on Monday, May 11th, 2020

2020-05-02 08:08:29 | One Thing To Remember About The AcelRx Pharmaceuticals, Inc. NASDAQ:ACRX Share Price

2020-04-30 06:00:00 | AcelRx Announces DSUVIA® Milestone C Approval and Provides Business Update

2020-04-24 06:11:10 | Bet on Rising P/E Investing With These Top 5 Stocks

2020-04-23 09:09:01 | AcelRx's Shares March Higher, Can It Continue?

2020-04-16 12:02:06 | 3 Compelling Penny Stocks With at Least 50% Upside Potential

2020-04-02 12:28:04 | The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore

2020-04-01 08:18:12 | After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys

2020-03-27 12:00:04 | All You Need to Know About AcelRx Pharmaceuticals ACRX Rating Upgrade to Buy

2020-03-18 06:05:01 | AcelRx Pharmaceuticals, Inc. Just Reported, And Analysts Assigned A US$6.40 Price Target

2020-03-17 17:50:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Tetraphase Pharmaceuticals, Inc. with AcelRx Pharmaceuticals, Inc. is Fair to TTPH Shareholders

2020-03-17 13:47:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Tetraphase Pharmaceuticals, Inc.

2020-03-17 03:23:34 | Edited Transcript of ACRX earnings conference call or presentation 16-Mar-20 12:30pm GMT

2020-03-16 17:10:00 | TETRAPHASE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger

2020-03-16 09:02:11 | AcelRx Pharmaceuticals: Q4 Earnings Insights

2020-03-16 07:35:00 | AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

2020-03-16 07:30:00 | AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

2020-03-11 19:50:00 | AcelRx to Announce Fourth Quarter 2019 Results on Monday, March 16th, 2020

2020-03-10 14:25:00 | AcelRx Announces Confirmed Timing of Department of Defense Milestone C Meeting for April

2020-03-06 11:55:00 | AcelRx Announces Agreement for an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Spine Surgery

2020-02-27 12:30:05 | Earnings Preview: AcelRx Pharmaceuticals ACRX Q4 Earnings Expected to Decline

2020-02-24 10:28:03 | AcelRx ACRX to Report Q4 Earnings: What's in the Cards?

2020-02-07 06:49:26 | Should You Worry About AcelRx Pharmaceuticals, Inc.'s NASDAQ:ACRX CEO Salary Level?

2020-01-27 17:45:10 | AcelRx Pharmaceuticals ACRX Stock Moves -1.14%: What You Should Know

2020-01-13 17:50:10 | AcelRx Pharmaceuticals ACRX Stock Sinks As Market Gains: What You Should Know

2020-01-13 07:00:00 | AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates

2020-01-07 10:21:03 | Soleno SLNO Ends Enrollment in Prader-Willi Syndrome Study

2020-01-07 09:51:02 | Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA

2020-01-07 09:17:02 | Catalyst Gives Preliminary Firdapse Estimates & Other Updates

2020-01-06 06:38:11 | Have Faith in Rising P/E: Play 5 Top-Ranked Stocks

2020-01-03 12:00:05 | AcelRx Pharmaceuticals ACRX Upgraded to Strong Buy: What Does It Mean for the Stock?

2020-01-03 09:07:02 | Top Ranked Momentum Stocks to Buy for January 3rd

2019-12-31 11:05:04 | Jazz Enrolls First Patient in Phase II/III Leukemia Study

2019-12-30 05:21:25 | How Much Are AcelRx Pharmaceuticals, Inc. NASDAQ:ACRX Insiders Spending On Buying Shares?